Understanding the A1c Test and Its Role in Diabetes Management

The hemoglobin A1c (A1c) test has long been a cornerstone of diabetes care, providing a convenient, non-fasting measure of average blood glucose over approximately two to three months. It reflects the percentage of hemoglobin proteins that have undergone glycation, making it a useful tool for both diagnosis and monitoring. The American Diabetes Association (ADA) recommends A1c targets of <7% for most nonpregnant adults with diabetes, and the test is widely used in clinical trials and everyday practice (ADA Standards of Care 2024). However, the assumption that A1c accurately reflects the true glycemic state in all patients is increasingly challenged, particularly in populations with obesity. The growing prevalence of obesity globally, often accompanied by insulin resistance and type 2 diabetes, demands a closer look at how body composition, inflammation, and red blood cell physiology influence glycated hemoglobin levels. Without this understanding, clinicians risk misclassifying glycemic control, leading to inappropriate treatment intensification or de-escalation.

Why Obesity Complicates A1c Accuracy

Obesity—defined as a body mass index (BMI) of 30 kg/m² or higher—introduces multiple physiological changes that can distort the relationship between blood glucose and A1c. These factors are not merely statistical nuisances; they represent genuine confounding variables that can cause A1c to either overestimate or underestimate true glycemic control. Recognizing these mechanisms is essential for interpreting A1c results in obese patients with diabetes.

Altered Hemoglobin Turnover and Red Blood Cell Lifespan

The A1c calculation depends on the assumption that red blood cells (RBCs) have a normal lifespan of approximately 120 days. In obesity, however, RBC survival can be shortened or prolonged. Chronic low-grade inflammation, a hallmark of obesity, accelerates RBC clearance via increased oxidative stress and altered erythrocyte membrane properties (Malkani et al., 2017). Shorter RBC lifespan reduces the time available for glucose-hemoglobin binding, resulting in a falsely low A1c relative to actual average glucose levels. Conversely, conditions that prolong RBC survival—such as iron deficiency anemia, which is also more common in obesity due to poor nutrition or bariatric surgery—can raise A1c without a true increase in glycemia. This bidirectional effect creates a “gray zone” where A1c misleads clinicians.

Hemodilution and Plasma Volume Expansion

Obesity is associated with expanded plasma volume due to increased total body water and decreased plasma osmolality. This hemodilution lowers the concentration of hemoglobin and red blood cells per unit of blood. Since A1c is expressed as a percentage of total hemoglobin, any reduction in hemoglobin concentration can artificially decrease the measured A1c fraction, even when absolute glycation per red blood cell is unchanged. Studies have shown that obese individuals with normal glucose tolerance can have A1c levels that are 0.2–0.4% lower than their non-obese counterparts after adjusting for age and sex, attributable partly to dilutional effects (Zaccardi et al., 2016). In patients with severe obesity (BMI >40 kg/m²), this discrepancy may be even larger, masking poor glycemic control.

Comorbid Conditions That Skew A1c

Obesity frequently coexists with medical conditions that independently alter A1c independent of blood glucose. Chronic kidney disease (CKD), present in up to 40% of obese patients with diabetes, reduces RBC lifespan due to uremic toxins and anemia of chronic disease. The resulting shortened RBC survival lowers A1c. Additionally, treatment with erythropoiesis-stimulating agents increases the proportion of young RBCs with less exposure to glucose, further deflating A1c. On the other hand, iron deficiency—common in premenopausal women even without obesity—increases glycation of hemoglobin by reducing its turnover, raising A1c spuriously. Inflammatory mediators such as interleukin-6 and TNF-alpha, elevated in obesity, also enhance glycation rates independently of glucose concentration, adding another layer of complexity (Cohen et al., 2009). These comorbidities are often underappreciated when clinicians rely solely on A1c.

Ethnic and Racial Variability in Glycation

Obesity disproportionately affects certain ethnic groups, including African Americans, Hispanics, and South Asians, who also exhibit differences in hemoglobin glycation rates compared to Caucasians. Even after controlling for mean blood glucose, African Americans have been shown to have A1c levels 0.2–0.4% higher than whites (Selvin et al., 2017). This disparity is not fully explained by hemoglobin variants, anemia, or socioeconomic factors. In the context of obesity, these genetic differences are magnified: the combination of elevated basal glycation and inflammatory modulation can push A1c beyond clinically meaningful thresholds, leading to overestimation of glycemic burden and potentially unnecessary medication escalation. Until more inclusive glucose monitoring methods become standard, clinicians must remain vigilant about ethnic-specific cutoffs and consider alternative metrics in diverse populations.

Discrepancies Between A1c and Other Metrics

Several clinical studies have directly compared A1c with continuous glucose monitoring (CGM) or fructosamine in obese cohorts and found significant discordance. One meta-analysis reported that in patients with BMI > 35 kg/m², the sensitivity of A1c to detect true hyperglycemia (defined by CGM time above range) was only around 65%, with a positive predictive value of 70% (Barzegar et al., 2019). This means that nearly one in three obese patients with poor glycemic control—as documented by CGM—would be incorrectly classified as having adequate control based on A1c alone. Such misclassification can delay critical therapy adjustments, increasing the risk of diabetic complications over time.

Clinical Implications of Inaccurate A1c in Obese Patients

The ramifications of relying on a flawed metric extend beyond laboratory curiosity. When A1c is artificially low, patients may feel falsely reassured while their true average glucose remains elevated. This can lead to inadequate titration of antidiabetic medications, persistent hyperglycemia, and accelerated microvascular complications such as retinopathy and nephropathy. Conversely, an artificially high A1c may prompt aggressive treatment that causes hypoglycemia and weight gain—particularly problematic in obesity where weight neutrality or loss is a therapeutic goal. Moreover, clinical trial inclusion criteria often use A1c thresholds, potentially excluding obese patients who otherwise meet glycemic criteria based on CGM or fructosamine. This can bias research toward non-obese participants, reducing the generalizability of findings to the population that most needs them.

In bariatric surgery candidates with type 2 diabetes, preoperative A1c is often used to assess diabetes severity and predict remission. Studies have shown that A1c underestimates hyperglycemia in this group, leading to misclassification of surgical eligibility or postoperative expectations. Postoperatively, rapid weight loss and metabolic improvements further confound A1c measurements due to changes in red cell turnover secondary to malnutrition, anemia, or reduced inflammation (Suastegui et al., 2019). Thus, both pre- and post-bariatric glycemic assessment warrants a more nuanced approach.

Alternative and Complementary Methods for Glycemic Assessment

Given the limitations of A1c in obesity, clinicians should adopt a multimodal monitoring strategy. No single test is perfect, but combining multiple tools provides a more complete picture of glycemic status.

Fructosamine and Glycated Albumin

Fructosamine measures the glycation of all serum proteins, primarily albumin, and reflects glycemic control over the preceding two to three weeks. Because albumin has a shorter half-life (approximately 14 days) and is not affected by RBC lifespan, fructosamine can circumvent many of the pitfalls of A1c in obese patients. However, it is influenced by changes in protein metabolism—common in obesity due to chronic inflammation, liver dysfunction, and nephropathy—which can alter albumin concentrations. Glycated albumin (GA) is a more specific fraction that correlates well with CGM metrics and may be less affected by anemia or hemodilution. In several Asian cohorts of obese patients with type 2 diabetes, GA has shown better correlation with postprandial hyperglycemia than A1c. Despite its promise, GA testing is not yet widely available in many clinical settings and lacks standardized reference ranges (Koga & Kasayama, 2015). Nevertheless, when A1c is unreliable, ordering a fructosamine or GA can provide actionable short-term data.

Continuous Glucose Monitoring (CGM)

CGM has revolutionized diabetes management by providing real-time interstitial glucose readings every few minutes. It captures glycemic variability, time in range (TIR), and nocturnal patterns that A1c simply cannot. For obese patients, CGM is particularly valuable because it directly quantifies hyperglycemia without relying on hemoglobin kinetics. The ADA now endorses CGM as a standard tool for assessing glycemic control, especially when A1c may be misleading. Studies have shown that CGM-derived metrics such as TIR and time above range (TAR) correlate more strongly with diabetes complications than A1c in obese populations. The main barriers remain cost, access, and patient adherence, but in patients with large discrepancies between A1c and self-monitoring, CGM should be strongly considered. Emerging evidence suggests that even intermittent use—such as two-week sessions every quarter—can offer sufficient data for clinical decision-making (ADA CGM Guidance).

Self-Monitoring of Blood Glucose (SMBG)

Traditional finger-stick capillary glucose testing remains a practical, low-cost complement to laboratory tests. In obese patients, SMBG is essential for tracking daily fluctuations, postprandial spikes, and treatment responses. However, its utility depends on the frequency and adherence; many obese patients test infrequently due to discomfort or lack of motivation. When combined with structured glucose diaries or flash glucose monitoring (e.g., intermittently scanned CGM), SMBG can identify patterns that A1c or fructosamine miss. Clinicians should encourage paired testing (before and after meals) to assess the glycemic impact of specific foods and medications. SMBG is particularly useful in the pre- and post-bariatric setting to detect both hyperglycemia and hypoglycemia from dumping syndrome.

1,5-Anhydroglucitol (Glycomark)

1,5-AG is a marker of postprandial hyperglycemia over the preceding one to two weeks. It is excreted by the kidneys and competes with glucose for reabsorption; when glucose levels are high, less 1,5-AG is reabsorbed, leading to low serum levels. The test is sensitive to short-term glycemic excursions and is not affected by obesity per se. However, it requires normal renal function, which can be compromised in obese patients with diabetic nephropathy or hypertension. For patients with well-preserved eGFR, 1,5-AG can be a useful adjunct to assess whether postprandial hyperglycemia is being missed by A1c alone (Dungan et al., 2009). Its major limitation is that it becomes unreliable in the presence of renal impairment, which is common in long-standing diabetes and obesity.

Combining Multiple Metrics for Comprehensive Assessment

No single alternative test is perfect. The optimal approach in obese patients is to use a combination of A1c (with caveats), fructosamine or GA, and CGM data, along with careful clinical correlation. For example, if A1c suggests an average glucose of 180 mg/dL but CGM shows mean glucose of 210 mg/dL with significant time above 250 mg/dL, the clinician should trust the CGM data and intensify therapy accordingly. Similarly, if a patient with obesity has an A1c of 6.8% but reports frequent hypoglycemia, a CGM or fructosamine may reveal that the A1c is inflated by periods of hyperglycemia that are not representative of overall stability. The ADA’s “Standards of Care in Diabetes” now explicitly recommend that clinicians consider alternatives to A1c in conditions affecting red cell turnover, including obesity, and suggest using CGM as a complementary measure (ADA 2024 Standards of Care, Section 6).

Practical Recommendations for Clinicians

When to Suspect A1c Inaccuracy

Clinicians should suspect A1c inaccuracy in any obese patient with a BMI > 35 kg/m², especially if there is discordance between A1c and self-monitored glucose readings, or if the patient has a history of anemia, renal impairment, inflammatory diseases, or recent blood loss. Symptoms of uncontrolled diabetes (polyuria, polydipsia, weight loss) despite a “controlled” A1c should also raise suspicion. In such cases, ordering a complete blood count, reticulocyte count, and iron studies can help identify red cell abnormalities. Ethnicity should also be considered; a patient of African or Hispanic descent may need a different A1c target. The rule of thumb: if the A1c does not match clinical expectations, investigate further before adjusting therapy.

Using CGM as a Gold Standard

In patients with confirmed or suspected A1c discordance, a two-week trial of professional (blinded) CGM can provide definitive data. The CGM-derived glucose management indicator (GMI) was developed to approximate A1c from CGM data, but it corrects for some of the non-glycemic factors that confound A1c. Even if GMI is slightly different from lab A1c, the TIR and TAR give actionable insights. For obese patients, targeting a TIR > 70% (70–180 mg/dL) and TAR < 25% (> 180 mg/dL) can be more meaningful than aiming for a specific A1c number. When CGM is not available, ordering fructosamine or GA every 2–3 weeks for a few cycles can provide a reliable trend.

Tailoring Therapy Based on Accurate Data

Once a more accurate picture of glycemic status is obtained, therapy adjustments should be aligned with the true deficit. For example, if a patient with obesity has a low A1c due to hemodilution but high postprandial glucose detected by CGM, adding a GLP-1 receptor agonist (which also promotes weight loss) or a short-acting insulin secretagogue may be appropriate. Conversely, if A1c is artificially elevated due to iron deficiency, correcting the iron deficiency may drop A1c to a more accurate level without any change in diabetes medications. Bariatric candidates may benefit from CGM-guided insulin reduction preoperatively to minimize the risk of postoperative hypoglycemia. In all cases, shared decision-making with the patient, explaining why multiple tests are used, improves adherence and trust.

Conclusion

The A1c test remains a valuable screening and monitoring tool for diabetes, but its accuracy is compromised in obese patients due to multiple non-glycemic factors including altered RBC lifespan, hemodilution, comorbidities, and ethnic variability. Clinicians must recognize these limitations and adopt a multimodal glycemic assessment strategy that incorporates fructosamine, glycated albumin, CGM, and SMBG as needed. By moving beyond a one-size-fits-all reliance on A1c, healthcare providers can improve the precision of diabetes management in the growing population of patients with obesity, ultimately reducing complications and improving outcomes. The evidence is clear: in the era of personalized medicine, glycemic monitoring must be tailored to the individual—not to a number alone.